China has officially granted its first-ever commercial approval for a brain-computer interface (BCI) implant, marking a significant milestone in medical technology. The National Medical Products Administration of China authorized the startup Neuracle Technology to market its innovative device, which is specifically designed to assist individuals suffering from partial paralysis due to spinal cord injuries. This regulatory breakthrough positions China at the forefront of neurotechnology, as the country continues to prioritize the development of advanced medical interfaces.
The BCI-implant functions by surgically placing a device near or within the brain to read and stimulate neural signals directly. By converting the brain's electrical activity into actionable commands for external computers, the system allows patients to control prosthetic limbs using only their thoughts. According to the developers, the device has already undergone successful testing on 36 patients, demonstrating its capability to help individuals regain the ability to grasp objects with their hands. Unlike more invasive systems, the Neuracle implant is installed outside the brain's dura mater, making it a safer, albeit more specialized, solution for those with partial mobility issues.
The Chinese government has identified BCI technology as one of its six core strategic sectors, pledging to streamline regulatory processes and establish clear reimbursement rules to accelerate market entry. This proactive stance has triggered a notable surge in the stock prices of various domestic technology firms. While global interest in this field is intensifying, including significant investments in the United States, the competitive landscape remains fierce. Notably, American companies such as Neuralink, founded by billionaire Elon Musk, are currently limited to human clinical trials, giving Chinese developers a potential head start in the commercialization of these life-changing medical devices.
Read “Zamin” on Telegram!
